Document is current
Any future updates will be listed below
-
Authors
Salazar-Vizcaya, Luisa https://orcid.org/0000-0003-0527-0141
Nicca, Dunja https://orcid.org/0000-0002-4133-8177
Christinet, Vanessa
Kouyos, Roger D. https://orcid.org/0000-0002-9220-8348
Vock, Florian
Andresen, Sara
Lehner, Andreas
Haerry, David
Günthard, Huldrych F.
Schmidt, Axel J.
Rauch, Andri
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (324730_179567)
University of Bern
- License Information
-
More Information
Article History
Received: 11 January 2024
Revised: 29 April 2025
Accepted: 30 April 2025
First Online: 7 July 2025
Declarations
:
: AR reports support to his institution for advisory boards and/or travel grants from MSD, Gilead Sciences, Pfizer, and Abbvie; and an investigator initiated trial grant from Gilead Sciences. All remuneration went to his home institution and not to AR personally, and all remuneration was provided outside the submitted work; HFG has received grants from the SNF; SHCS; Yvonne Jacob Foundation; University of Zurich’s Clinical Research Priority Program, viral disease; Zurich Primary HIV Infection; Systems.X; National Institutes of Health; Gilead Sciences; and personal fees from Merck, Gilead Sciences, ViiV, GSK, Janssen, Johnson and Johnson, and Novartis, for consultancy or DSMB membership and a travel grant from Gilead.
: Because all data were collected anonymously without any identifying personal data, this work did not need permission from the ethical committee (Swiss Federal Act on Research involving Human Beings, chapters 2b-c) (Federal Office of Public Health. (). Federal act on research involving human beings).
